Scientists at CSIRO, Australia’s national science agency, in partnership with Melbourne Genomics Health Alliance, have developed an Australian-first digital conversation agent (a ‘chatbot’) that could support patients in making informed decisions about genomic testing for future health risks.
Dubbed ‘Edna’ (‘electronic-DNA’), the chatbot is the first of its kind globally developed specifically to support genetic counselling for adults being tested to ascertain future risk of preventable or treatable conditions (known as ‘additional findings’).
Derived from real-world patient interactions, Edna is designed to address repetitive or predictable aspects of genetic counselling for additional findings.
This frees genetic counsellors to focus their highly specialised skills on deeper and more specific issues relevant to patients.
“If the healthcare system were to provide this kind of testing – which is beyond immediate medical need – one of the challenges is the genetic counselling time required to support patients’ informed consent,” said Prof Clara Gaff, Executive Director of Melbourne Genomics, a ten-member alliance that includes CSIRO.
“This prototype chatbot shows how we might employ technology to meet this need.”
CSIRO researcher Dr Dana Bradford, who led development of Edna, said a chatbot simulates human conversation through artificial intelligence. For chatbots to accurately recognise content in human speech – and provide a meaningful response – they need a large body of data to draw on, called a chatbot ‘brain’.
“Many chatbot brains are developed from open source data but this is inadequate for highly specialised fields like patient decision-making,” said Dr Bradford.
“Our joint team developed Edna’s brain by systematically analysing transcripts of actual genetic counselling sessions for additional findings. This expert basis for Edna makes all the difference in applying this new technology.”
Edna can collect a patient’s family history and analyse human responses for signals that interaction with a genetic counsellor may be needed.
Edna’s development was part of a larger proof-of-concept study led by Melbourne Genomics to better understand the implications of offering additional findings testing to patients in Victoria.
“The Edna chatbot represents a significant movement toward feasible, real-world-informed digital health processes that can support patients’ informed decision-making about testing for future disease risk,” said Prof Gaff.
Currently undergoing a feasibility trial with patients, genetic counsellors and genetics students, Edna is slated to undergo a larger-scale patient trial in the near future.
“When built in partnership with healthcare experts and patients, chatbot technology has enormous potential to provide and collect basic information in complex fields like genetics,” said Dr Bradford. “Not only is the service on-demand, so people can access it whenever they wish, but it could free up highly-skilled expert time to build more effective care.”
The Edna chatbot was recently published in the peer-reviewed journal Patient Education and Counseling.